Impact of Age on Short- and Long-Term Outcomes after Pancreatoduodenectomy for Periampullary Neoplasms.
Journal
Gastroenterology research and practice
ISSN: 1687-6121
Titre abrégé: Gastroenterol Res Pract
Pays: Egypt
ID NLM: 101475557
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
revised:
24
02
2020
accepted:
30
03
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
10
5
2020
Statut:
epublish
Résumé
Although mortality and morbidity of pancreatoduodenectomy (PD) have improved significantly over the past years, the impact of age for patients undergoing PD is still debated. This study is aimed at analyzing short- and long-term outcomes of PD in elderly patients. 124 consecutive patients who have undergone PD for pancreas neoplasms in our center between 2012 and 2017 were analyzed. Patients were divided into two groups: group I (<75 years) and group II (≥75 years). Demographic features and intraoperative and clinical-pathological data were collected. Primary endpoints were perioperative morbidity and mortality; complications were classified according to the Clavien-Dindo Score. Secondary endpoints included feasibility of adjuvant treatment and overall survival rates. A total of 106 patients were included in this study. There were 73 (68.9%) patients in group I and 33 (31.1%) in group II. Perioperative deceases were 4 (3.6%), and postoperative pancreatic fistulas were 34 (32.1%). Significant difference between two groups was demonstrated for the ASA Score ( PD can be performed safely in elderly patients. Advanced age should not be an absolute contraindication for PD, even if greater frailty should be considered. The outcome of elderly patients who have undergone PD is similar to that of younger patients, even though adjuvant treatment administration is significantly lower, demonstrating that surgery remains the main therapeutic option.
Sections du résumé
BACKGROUND
BACKGROUND
Although mortality and morbidity of pancreatoduodenectomy (PD) have improved significantly over the past years, the impact of age for patients undergoing PD is still debated. This study is aimed at analyzing short- and long-term outcomes of PD in elderly patients.
METHODS
METHODS
124 consecutive patients who have undergone PD for pancreas neoplasms in our center between 2012 and 2017 were analyzed. Patients were divided into two groups: group I (<75 years) and group II (≥75 years). Demographic features and intraoperative and clinical-pathological data were collected. Primary endpoints were perioperative morbidity and mortality; complications were classified according to the Clavien-Dindo Score. Secondary endpoints included feasibility of adjuvant treatment and overall survival rates.
RESULTS
RESULTS
A total of 106 patients were included in this study. There were 73 (68.9%) patients in group I and 33 (31.1%) in group II. Perioperative deceases were 4 (3.6%), and postoperative pancreatic fistulas were 34 (32.1%). Significant difference between two groups was demonstrated for the ASA Score (
CONCLUSION
CONCLUSIONS
PD can be performed safely in elderly patients. Advanced age should not be an absolute contraindication for PD, even if greater frailty should be considered. The outcome of elderly patients who have undergone PD is similar to that of younger patients, even though adjuvant treatment administration is significantly lower, demonstrating that surgery remains the main therapeutic option.
Identifiants
pubmed: 32382261
doi: 10.1155/2020/1793051
pmc: PMC7183022
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1793051Informations de copyright
Copyright © 2020 Mario Gruppo et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Adv Surg. 2009;43:233-49
pubmed: 19845182
Semin Oncol. 2004 Apr;31(2):128-36
pubmed: 15112144
Pancreas. 2014 Mar;43(2):306-10
pubmed: 24518512
J Gastrointest Surg. 2005 Dec;9(9):1307-12
pubmed: 16332487
ANZ J Surg. 2017 Nov 30;88(7-8):E602-E605
pubmed: 29194898
HPB (Oxford). 2012 Oct;14(10):649-57
pubmed: 22954000
HPB (Oxford). 2012 Sep;14(9):583-8
pubmed: 22882194
Ann Surg. 2016 Oct;264(4):591-8
pubmed: 27355261
J Gastrointest Surg. 2006 Mar;10(3):347-56
pubmed: 16504879
HPB (Oxford). 2011 Dec;13(12):887-92
pubmed: 22081925
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Ann Surg Oncol. 2010 Apr;17(4):991-7
pubmed: 20108122
Br J Cancer. 2014 Jan 21;110(2):313-9
pubmed: 24263063
J Am Coll Surg. 2013 Jan;216(1):1-14
pubmed: 23122535
World J Surg. 2006 Nov;30(11):1992-2001; discussion 2002-3
pubmed: 16957825
Arch Surg. 2009 Oct;144(10):950-6
pubmed: 19841364
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
Br J Anaesth. 2007 Oct;99(4):500-8
pubmed: 17681972
Crit Care. 2013 Sep 08;17(5):R191
pubmed: 24010849
J Gastrointest Surg. 2010 Nov;14(11):1826-31
pubmed: 20714937
Surgeon. 2012 Jun;10(3):128-36
pubmed: 22525414
Arch Surg. 2001 Apr;136(4):391-8
pubmed: 11296108
Ann Surg. 2003 Aug;238(2):170-7
pubmed: 12894008
J Surg Res. 2015 Oct;198(2):441-9
pubmed: 25930169
Surgery. 2018 Sep;164(3):539-545
pubmed: 29929759
World J Gastroenterol. 2017 May 7;23(17):3077-3083
pubmed: 28533664
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Am J Surg. 2014 Apr;207(4):540-8
pubmed: 24560585
Langenbecks Arch Surg. 2013 Apr;398(4):531-8
pubmed: 23462741